Literature DB >> 22369387

Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Yang Zhou1, Young-Seung Kim, Xin Lu, Shuang Liu.   

Abstract

The main objective of this study is to explore the impact of cyclic RGD peptides and (99m)Tc chelates on biological properties of (99m)Tc radiotracers. Cyclic RGD peptide conjugates, HYNIC-K(NIC)-RGD(2) (HYNIC = 6-hydrazinonicotinyl; RGD(2) = E[c(RGDfK)](2) and NIC = nicotinyl), HYNIC-K(NIC)-3G-RGD(2) (3G-RGD(2) = Gly-Gly-Gly-E[Gly-Gly-Gly-c(RGDfK)](2)), and HYNIC-K(NIC)-3P-RGD(2) (3P-RGD(2) = PEG(4)-E[PEG(4)-c(RGDfK)](2)), were prepared. Macrocyclic (99m)Tc complexes [(99m)Tc(HYNIC-K(NIC)-RGD(2))(tricine)] (1), [(99m)Tc(HYNIC-K(NIC)-3G-RGD(2))(tricine)] (2), and [(99m)Tc(HYNIC-K(NIC)-3P-RGD(2))(tricine)] (3) were evaluated for their biodistribution and tumor-targeting capability in athymic nude mice bearing MDA-MB-435 human breast tumor xenografts. It was found that 1, 2, and 3 could be prepared with high specific activity (∼111 GBq/μmol). All three (99m)Tc radiotracers have two major isomers, which show almost identical uptake in tumors and normal organs. Replacing the bulky and highly charged [(99m)Tc(HYNIC)(tricine)(TPPTS)] (TPPTS = trisodium triphenylphosphine-3,3',3″-trisulfonate) with a smaller [(99m)Tc(HYNIC-K(NIC))(tricine)] resulted in less uptake in the kidneys and lungs for 3. Surprisingly, all three (99m)Tc radiotracers shared a similar tumor uptake (1, 5.73 ± 0.40%ID/g; 2, 5.24 ± 1.09%ID/g; and 3, 4.94 ± 1.71%ID/g) at 60 min p.i. The metabolic stability of (99m)Tc radiotracers depends on cyclic RGD peptides (3P-RGD(2) > 3G-RGD(2) ∼ RGD(2)) and (99m)Tc chelates ([(99m)Tc(HYNIC)(tricine)(TPPTS)] > [(99m)Tc(HYNIC-K(NIC))(tricine)]). Immunohistochemical studies revealed a linear relationship between the α(v)β(3) expression levels and tumor uptake or tumor/muscle ratios of 3, suggesting that 3 is useful for monitoring the tumor α(v)β(3) expression. Complex 3 is a very attractive radiotracer for detection of integrin α(v)β(3)-positive tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369387      PMCID: PMC3310279          DOI: 10.1021/bc200631g

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  31 in total

1.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression.

Authors:  Yang Zhou; Young-Seung Kim; Sudipta Chakraborty; Jiyun Shi; Haijuan Gao; Shuang Liu
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

Review 3.  Imaging angiogenesis: applications and potential for drug development.

Authors:  Janet C Miller; Homer H Pien; Dushyant Sahani; A Gregory Sorensen; James H Thrall
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

4.  New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc.

Authors:  D S Edwards; S Liu; J A Barrett; A R Harris; R J Looby; M C Ziegler; S J Heminway; T R Carroll
Journal:  Bioconjug Chem       Date:  1997 Mar-Apr       Impact factor: 4.774

5.  Molecular imaging in radiotherapy planning for head and neck tumors.

Authors:  Vincent Grégoire; Arturo Chiti
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

6.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer.

Authors:  Shuang Liu; Young-Seung Kim; Wen-Yuan Hsieh; Subramanya Gupta Sreerama
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

7.  Phosphine-containing HYNIC derivatives as potential bifunctional chelators for (99m)Tc-labeling of small biomolecules.

Authors:  Ajay Purohit; Shuang Liu; Dave Casebier; D Scott Edwards
Journal:  Bioconjug Chem       Date:  2003 Jul-Aug       Impact factor: 4.774

8.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.

Authors:  Jiyun Shi; Young-Seung Kim; Shizhen Zhai; Zhaofei Liu; Xiaoyuan Chen; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

9.  99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics.

Authors:  Jiyun Shi; Lijun Wang; Young-Seung Kim; Shizhen Zhai; Bing Jia; Fan Wang; Shuang Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-30       Impact factor: 9.236

10.  Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.

Authors:  Shuang Liu; Wen-Yuan Hsieh; Young Jiang; Young-Seung Kim; Subramanya G Sreerama; Xiaoyuan Chen; Bing Jia; Fan Wang
Journal:  Bioconjug Chem       Date:  2007-03-07       Impact factor: 4.774

View more
  13 in total

1.  Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging.

Authors:  Zuo-Quan Zhao; Yong Yang; Wei Fang; Shuang Liu
Journal:  Nucl Med Biol       Date:  2016-02-27       Impact factor: 2.408

Review 2.  Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2015-08-03       Impact factor: 4.774

3.  Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules.

Authors:  Shundong Ji; Yang Zhou; Guoqiang Shao; Shuang Liu
Journal:  Bioconjug Chem       Date:  2013-04-08       Impact factor: 4.774

4.  (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.

Authors:  Shundong Ji; Andrzej Czerwinski; Yang Zhou; Guoqiang Shao; Francisco Valenzuela; Paweł Sowiński; Satendra Chauhan; Michael Pennington; Shuang Liu
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

5.  (99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.

Authors:  Tong Fu; Wei Qu; Fan Qiu; Yan Li; Guoqiang Shao; Wei Tian; Zichun Hua; Yingjian Zhang; Feng Wang
Journal:  Cancer Biother Radiopharm       Date:  2014-10-06       Impact factor: 3.099

6.  Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy.

Authors:  Haiyan Chen; Xin Zhang; Shuhang Dai; Yuxiang Ma; Sisi Cui; Samuel Achilefu; Yueqing Gu
Journal:  Theranostics       Date:  2013-08-03       Impact factor: 11.556

7.  Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.

Authors:  Shundong Ji; Yumin Zheng; Guoqiang Shao; Yang Zhou; Shuang Liu
Journal:  Theranostics       Date:  2013-10-12       Impact factor: 11.556

8.  FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues.

Authors:  Yumin Zheng; Shundong Ji; Andrzej Czerwinski; Francisco Valenzuela; Michael Pennington; Shuang Liu
Journal:  Bioconjug Chem       Date:  2014-10-22       Impact factor: 4.774

9.  Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides.

Authors:  Yong Yang; Shundong Ji; Shuang Liu
Journal:  Bioconjug Chem       Date:  2014-08-21       Impact factor: 4.774

10.  Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.

Authors:  Shundong Ji; Yang Zhou; Martin J Voorbach; Guoqiang Shao; Yumin Zhang; Gerard B Fox; Daniel H Albert; Yanping Luo; Shuang Liu; Sarah R Mudd
Journal:  J Pharmacol Exp Ther       Date:  2013-06-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.